SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.

Kohli, JS; Mir, H; Wasif, A; Chong, H; Akhras, V; Kumar, R; Nagore, E; Bennett, DC (2017) ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression. Oncotarget, 8 (61). pp. 104408-104417. ISSN 1949-2553 https://doi.org/10.18632/oncotarget.22254
SGUL Authors: Bennett, Dorothy Catherine

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview

Abstract

TERT (telomerase reverse transcriptase) is the catalytic component of telomerase. TERT shows little expression in normal somatic cells but is commonly re-expressed in cancers, facilitating immortalization. Recently-discovered TERT promoter mutations create binding sites for ETS-family transcription factors to upregulate TERT. ETS1 is reported to be important for TERT upregulation in melanoma. However it is unclear when in melanoma progression TERT and ETS1 proteins are expressed. To elucidate this question, ETS1 and TERT immunohistochemistry were performed on a panel of benign (n=27) and dysplastic nevi (n=34), radial growth phase (n=29), vertical growth phase (n=25) and metastatic melanomas (n=27). Lesions were scored by percentage of positive cells. ETS1 was readily detectable in all lesions, but not in normal melanocytes. TERT was located in either the nucleolus, the nucleoplasm (non-nucleolar) or both. Non-nucleolar TERT increased in prevalence with progression, from 19% of benign nevi to 78% of metastases. It did not however correlate with cell proliferation (Ki-67 immunostaining), nor differ significantly in prevalence between primary melanomas with or without a TERT promoter mutation. These results demonstrate that ETS1 is expressed very early in melanoma progression, and interestingly only non-nucleolar TERT correlates clearly in prevalence with melanoma progression. It can be acquired at various stages and by mechanisms other than promoter mutations.

Item Type: Article
Additional Information: Kohli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: ETS1, TERT, melanoma, nevus, nucleolus
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Oncotarget
ISSN: 1949-2553
Language: eng
Dates:
DateEvent
28 November 2017Published
1 November 2017Published Online
3 October 2017Accepted
Publisher License: Creative Commons: Attribution 3.0
Projects:
Project IDFunderFunder ID
097832/Z/11/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
01KT15511TRANSCANUNSPECIFIED
PubMed ID: 29262649
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/109459
Publisher's version: https://doi.org/10.18632/oncotarget.22254

Actions (login required)

Edit Item Edit Item